Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder

Full text
Author(s):
Martins-de-Souza, Daniel
Total Authors: 1
Document type: Journal article
Source: DIALOGUES IN CLINICAL NEUROSCIENCE; v. 16, n. 1, p. 63-73, MAR 2014.
Web of Science Citations: 34
Abstract

Omics technologies emerged as complementary strategies to genomics in the attempt to understand human illnesses. In general, proteomics technologies emerged earlier than those of metabolomics for major depressive disorder (MDD) research, but both are driven by the identification of proteins and/or metabolites that can delineate a comprehensive characterization of MDD's molecular mechanisms, as well as lead to the identification of biomarker candidates of all types-prognosis, diagnosis, treatment, and patient stratification. Also, one can explore protein and metabolite interactomes in order to pinpoint additional molecules associated with the disease that had not been picked up initially. Here, results and methodological aspects of MDD research using proteomics, metabolomics, and protein interactomics are reviewed, focusing on human samples. (C) 2014, AICH - Servier Research Group (AU)

FAPESP's process: 13/08711-3 - Developing a predictive test for a successful medication response and understanding the molecular bases of schizophrenia through proteomics
Grantee:Daniel Martins-de-Souza
Support Opportunities: Research Grants - Young Investigators Grants